Somatostatin analog challenge test in the pre-surgical management of ACTH-secreting pheochromocytoma. (25th November 2019)
- Record Type:
- Journal Article
- Title:
- Somatostatin analog challenge test in the pre-surgical management of ACTH-secreting pheochromocytoma. (25th November 2019)
- Main Title:
- Somatostatin analog challenge test in the pre-surgical management of ACTH-secreting pheochromocytoma
- Authors:
- Rossini, Alessandro
Perticone, Francesca
Frosio, Laura
Schiavo Lena, Marco
Lanzi, Roberto - Abstract:
- Abstract : Summary: ACTH-secreting pheochromocytoma is a very rare cause of Cushing's syndrome, with a high morbidity and mortality risk due to both cortisol and catecholamines excess. We report the case of a 45-year-old female patient with a 3 cm, high-density, left adrenal mass, diagnosed as an ACTH-secreting pheochromocytoma. The biochemical sensitivity of the tumor to somatostatin analogues was tested by a 100 μg s.c. octreotide administration, which led to an ACTH and cortisol reduction of 50 and 25% respectively. In addition to alpha and beta blockers, preoperative approach to laparoscopic adrenalectomy included octreotide, a somatostatin analogue, together with ketoconazole, in order to achieve an adequate pre-surgical control of cortisol release. Histopathological assessment confirmed an ACTH-secreting pheochromocytoma expressing type 2 and 5 somatostatin receptors (SSTR-2 and -5). Learning points: ACTH-secreting pheochromocytomas represent a rare and severe condition, characterized by high morbidity and mortality risk. Surgical removal of the adrenal mass is the gold standard treatment, but adequate medical therapy is required preoperatively to improve the surgical outcome and to avoid major complications. Somatostatin analogs, in addition to other medications, may represent a useful therapeutic option for the presurgical management of selected patients. In this sense, the octreotide challenge test is a useful tool to predict favorable therapeutic response to theAbstract : Summary: ACTH-secreting pheochromocytoma is a very rare cause of Cushing's syndrome, with a high morbidity and mortality risk due to both cortisol and catecholamines excess. We report the case of a 45-year-old female patient with a 3 cm, high-density, left adrenal mass, diagnosed as an ACTH-secreting pheochromocytoma. The biochemical sensitivity of the tumor to somatostatin analogues was tested by a 100 μg s.c. octreotide administration, which led to an ACTH and cortisol reduction of 50 and 25% respectively. In addition to alpha and beta blockers, preoperative approach to laparoscopic adrenalectomy included octreotide, a somatostatin analogue, together with ketoconazole, in order to achieve an adequate pre-surgical control of cortisol release. Histopathological assessment confirmed an ACTH-secreting pheochromocytoma expressing type 2 and 5 somatostatin receptors (SSTR-2 and -5). Learning points: ACTH-secreting pheochromocytomas represent a rare and severe condition, characterized by high morbidity and mortality risk. Surgical removal of the adrenal mass is the gold standard treatment, but adequate medical therapy is required preoperatively to improve the surgical outcome and to avoid major complications. Somatostatin analogs, in addition to other medications, may represent a useful therapeutic option for the presurgical management of selected patients. In this sense, the octreotide challenge test is a useful tool to predict favorable therapeutic response to the treatment. … (more)
- Is Part Of:
- Endocrinology, diabetes & metabolism case reports. (2019)
- Journal:
- Endocrinology, diabetes & metabolism case reports
- Issue:
- (2019)
- Issue Display:
- Issue 2019 (2019)
- Year:
- 2019
- Issue:
- 2019
- Issue Sort Value:
- 2019-0000-2019-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-11-25
- Subjects:
- Adult -- Female -- White -- Italy
Adrenal -- Adrenal -- ACTH -- Cortisol -- Metanephrines -- Phaeochromocytoma -- Cushing's syndrome -- Diabetes mellitus type 2
Hypercortisolaemia -- Diabetes mellitus type 2 -- Asthenia -- Pyrexia -- Weight loss -- Hypertension -- Hypokalaemia -- Hyperglycaemia -- Muscle atrophy -- Hypercortisolaemia -- Dehydration -- Leukocytosis -- Hypokalaemia -- Hyperglycaemia -- Hypothyroidism -- Hypogonadism -- ACTH -- Cortisol (serum) -- Cortisol, free (24-hour urine) -- Dexamethasone suppression -- Octreotide suppression test -- Somatostatin receptors* -- Histopathology -- Catecholamines (24-hour urine) -- Blood pressure -- Immunohistochemistry -- Metanephrines (urinary) -- Chromogranin A -- Haematoxylin and eosin staining -- Neuron-specific enolase -- IGF1 -- FT3 -- FT4 -- TSH -- Noradrenaline -- Normetanephrine -- Adrenaline -- CT scan -- CRH stimulation -- Laparoscopic adrenalectomy -- Somatostatin analogues -- Octreotide -- Alpha-blockers -- Beta-blockers -- Ketoconazole -- Metformin -- Pioglitazone -- Thiazolidinediones -- Hydrocortisone -- Glucocorticoids -- Doxazosin -- Atenolol -- Potassium chloride -- Insulin -- Amlodipine
Surgery
Novel treatment -- November -- 2019
Endocrinology -- Periodicals
Diabetes -- Periodicals
Diabetes Mellitus
Endocrinology
Diabetes
Endocrinology
Case Reports
Periodicals
Periodicals
616.4 - Journal URLs:
- https://www.edmcasereports.com/ ↗
http://bibpurl.oclc.org/web/73048 ↗ - DOI:
- 10.1530/EDM-19-0123 ↗
- Languages:
- English
- ISSNs:
- 2052-0573
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD Digital store
- Ingest File:
- 15634.xml